THE AASLD/FDA DILI CONFERENCE — Drug-induced Liver Injury:

New Developments and Innovations in Patients with Underlying Liver Disease, Cancer or COVID-19

April 20-22, 2021

Virtual Meeting

Sponsored by the American Association for the Study of Liver Diseases (AASLD) and the Food and Drug Administration, the Conference will connect international academic, industry and government participants who are dedicated to the study of DILI in chronic liver disease and cancer with topics spanning into innovative tools in the assessment of hepatotoxic risk and the growing number of best practice consensus reports by public-private partnerships management of DILI in different study populations. Additionally, the meeting will have planned sessions on the impact of COVID-19 in the evaluation and management of liver disease. With virtual communication tools, the conference will promote interactivity between faculty and the audience by with panel discussions and a live poster session.

• Meeting Event Link

THE LIVER MEETING® 2021

November 12-16, 2021

Anaheim, California

Sponsored by the American Association for the Study of Liver Diseases (AASLD), the Meeting has a focus on the science and clinical practice of hepatology, providing the latest information on hepatology research and patient care. Hepatologists from around the world exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.

• Meeting Event Link